Cardiovascular effects of erythropoietin: Anemia and beyond

Cardiology in Review

Volumn 14, Issue 4, 2006, Pages 200-204

  Guglin, Maya E ^a,b   Koul, Deepak ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b C 2800 Cardiology   (United States)

Author keywords

Anemia; Erythropoietin; Heart failure; Ischemia; Myocardial infarction

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERROUS GLUCONATE; FOLIC ACID; FUROSEMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ANEMIA; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CYTOKINE PRODUCTION; DATA BASE; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG MECHANISM; ERYTHROPOIESIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; REVIEW; ANIMAL; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE;

ANEMIA; ANIMALS; CARDIOVASCULAR DISEASES; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL ISCHEMIA;

EID: 33746290205     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000195223.85556.8e     Document Type: Review

References (49)

1. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Am Soc Nephrol. 1999;10:2392-2395.
2. Low-Friedrich I, Grutzmacher P, Marz W, et al. Therapy with recombinant human EPO reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol. 1991;11:54-60.
3. Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant. 1999;14(suppl 2):29-36.
4. Gaudard A, Varlet-Marie E, Bressolle F, et al. Drugs for increasing oxygen and their potential use in doping: a review. Sports Med. 2003;33:187-212.
5. Noakes TD. Tainted glory - doping and athletic performance. N Engl J Med. 351:847-849.
6. Erbayraktar S, Yilmaz O, Gokmen N, et al. EPO is a multifunctional tissue-protective cytokine. Curr Hematol Rep. 2003;2:465-470.
7. Stuckmann I, Evans S, Lassar AB. EPO and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. Dev Biol. 2003;255:334-349.
8. Leist M, Ghezzi P, Grasso G, et al. Derivatives of EPO that are tissue protective but not erythropoietic. Science. 2004;305:239-242.
9. Celik M, Gokmen N, Erbayraktar S, et al. EPO prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A. 2002;99:2258-2263.
10. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human EPO counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99:9450-9455.
11. Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with EPO enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732-1737.
12. Siren AL, Fratelli M, Brines M, et al. EPO prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.
13. Bianchi R, Buyukakilli B, Brines M, et al. EPO both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A. 2004;101:823-828.
14. Junk AK, Mammis A, Savitz SI, et al. EPO administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.
15. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial akt and attenuates progressive organ failure. Circulation. 2004;110:1006-1012.
16. Ehrenreich H, Hasselblatt M, Dembowski C, et al. EPO therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
17. Sterin-Borda L, Barcelo AC, Bozzini CE. EPO improves cardiac contractility in post-hypoxic mice. Br J Haematol. 2003;121:180-186.
18. Van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail. 2004;6:853-859.
19. Moon C, Krawczyk M, Ahn D, et al. EPO reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A. 2003;100:11612-11617.
20. Calvillo L, Latini R, Kajstura J, et al. Recombinant human EPO protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003;100:4802-4806.
21. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock. 2004;22:63-69.
22. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of EPO in the infarcted heart. J Clin Invest. 2003;112:999-1007.
23. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of EPO in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem. 2004;279:20655-20662.
24. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473-479.
25. Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2005;102:2046-2051.
26. Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail. 2004;10:S5-S9.
27. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002;4:681-686.
28. Van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44:63-67.
29. Silverberg D. Outcomes of anemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant. 2003;18:ii7-ii12.
30. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous EPO and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
31. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation. 2003;107:223-225.
32. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149-154.
33. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625-628.
34. Katz SD. Mechanisms and treatment of anemia in chronic heart failure. Congest Heart Fail. 2004;10:243-247.
35. Caiola K, Cheng JW. Use of erythropoietin in heart failure management. Ann Pharmacother. 2004;38:2145-2149.
36. McBride BF, White CM. Anemia management in heart failure: a thick review of thin data. Pharmacotherapy. 2004;24:757-767.
37. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955-962.
38. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous EPO and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780.
39. Silverberg DS, Wexler D, Blum M, et al. EPO should be part of congestive heart failure management. Kidney Int Suppl. 2003;S40-S47.
40. Silverberg DS, Wexler D, Blum B, et al. Anemia in chronic kidney disease and congestive heart failure. Blood Purif. 2003;21:124-130.
41. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous EPO and intravenous iron. Nephrol Dial Transplant. 2003;18:141-146.
42. Mancini DM, Katz SD, Lang CC, et al. Effect of EPO on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
43. Mitka M. Researchers probe anemia-heart failure link. JAMA. 2003;290:1835-1838.
44. Fyhrquist F, Karppinen K, Honkanen T, et al. EPO levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med. 1989;226:257-260.
45. Volpe M, Tritto C, Testa U, et al. Blood levels of EPO in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol. 1994;74:468-473.
46. Plata R, Cornejo A, Arratia C, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet. 2002;359:663-666.
47. Erturk S, Nergizoglu G, Ates K, et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1912-1916.
48. Cruz DN, Perazella MA, Abu-Alfa AK, et al. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of EPO resistance? Am J Kidney Dis. 1996;28:535-540.
49. Albitar S, Genin R, Fen-Chong M, et al. High dose enalapril impairs the response to EPO treatment in haemodialysis patients. Nephrol Dial Transplant. 1998;13:1206-1210.